Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-alpha/ribavirin therapy

Full text
Author(s):
Keppeke, Gerson Dierley [1] ; Calise, S. John [2] ; Chan, Edward K. L. [2] ; Andrade, Luis Eduardo C. [3, 1]
Total Authors: 4
Affiliation:
[1] Univ Fed Sao Paulo, Escola Paulista Med, Div Rheumatol, Rua Botucatu 740, BR-04023062 Sao Paulo, SP - Brazil
[2] Univ Florida, Dept Oral Biol, Gainesville, FL 32610 - USA
[3] Fleury Med & Hlth Labs, Div Immunol, BR-04102050 Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: WORLD JOURNAL OF GASTROENTEROLOGY; v. 22, n. 6, p. 1966-1974, FEB 14 2016.
Web of Science Citations: 11
Abstract

Chronic inflammation associated with hepatitis C virus (HCV) infection can lead to disabling liver diseases with progression to liver cirrhosis and hepatocellular carcinoma. Despite the recent availability of more effective and less toxic therapeutic options, in most parts of the world the standard treatment consists of a weekly injection of pegylated interferon a (IFN-alpha) together with a daily dose of ribavirin. HCV patients frequently present circulating non-organ-specific autoantibodies demonstrating a variety of staining patterns in the indirect immunofluorescence assay for antinuclear antibodies (ANA). Between 20% to 40% of HCV patients treated with IFN-a and ribavirin develop autoantibodies showing a peculiar ANA pattern characterized as rods and rings (RR) structures. The aim of this article is to review the recent reports regarding RR structures and anti-rods/rings (anti-RR) autoantibody production by HCV patients after IFN-alpha/ribavirin treatment. Anti-RR autoantibodies first appear around the sixth month of treatment and reach a plateau around the twelfth month. After treatment completion, anti-RR titers decrease/disappear in half the patients and remain steady in the other half. Some studies have observed a higher frequency of anti-RR antibodies in relapsers, i. e., patients in which circulating virus reappears after initially successful therapy. The main target of anti-RR autoantibodies in HCV patients is inosine-5 ` n-monophosphate dehydrogenase 2 (IMPDH2), the rate-limiting enzyme involved in the guanosine triphosphate biosynthesis pathway. Ribavirin (AU)

FAPESP's process: 11/12448-0 - Antibodies anti-"Rods & Rings", HCV and ribavirin/interferon: A human model of autoantibodies generation.
Grantee:Gerson Dierley Keppeke
Support Opportunities: Scholarships in Brazil - Doctorate